Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond
- 1 May 2008
- journal article
- review article
- Published by Elsevier BV in Laboratory Investigation
- Vol. 21, S16-S22
- https://doi.org/10.1038/modpathol.3801018
Abstract
No abstract availableKeywords
This publication has 68 references indexed in Scilit:
- MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibProceedings of the National Academy of Sciences of the United States of America, 2007
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007
- EGFR-T790M Is a Rare Lung Cancer Susceptibility Allele with Enhanced Kinase ActivityCancer Research, 2007
- Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clampBritish Journal of Cancer, 2006
- Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancerJCI Insight, 2006
- Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencingNature Medicine, 2006
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences of the United States of America, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibThe New England Journal of Medicine, 2004